Skip to main content

Table 1 Subject characteristics and facial nerve functional outcomes

From: Incidence of postoperative facial weakness in parotid tumor surgery: a tumor subsite analysis of 794 parotidectomies

No. (%)

Total patients

(n = 794)

Facial weakness

Temporarya

(n = 73, 9.2%)

Permanentb

(n = 41, 5.2%)

Gender

 Male

392 (49.4%)

32 (8.2%)

16 (4.1%)

 Female

402 (50.6%)

41 (10.2%)

25 (6.2%)

Age (years, mean, range)

48.9 [11–90]

52.4 [18–83]

54.4 [25–83]

Pathology (Supplementary Table S1)

 Benign tumors

651 (82.0%)

42 (6.5%)

22 (3.4%)

 Malignant tumorsc

143 (18.0%)

31 (21.7%)

19 (14.4%)

Tumor size (longest diameter, cm, mean, range)

2.6 [0.4–9.5]

3.0 [0.7–7.0]

3.1 [1.0–7.0]

Number of tumors

 Single

759 (95.6%)

67 (8.8%)

37 (4.9%)

 Multiple (≥ 2)

35 (4.4%)

6 (17.1%)

4 (11.4%)

Tumor subsite

 Superficial to the facial nerve

667 (84.0%)

44 (6.6%)

26 (3.9%)

 Deep to the facial nerve

70 (8.8%)

12 (17.1%)

4 (5.7%)

 Superficial and deep location (both)

57 (7.2%)

17 (29.8%)

11 (19.3%)

Extent of surgery

 Extracapsular dissection of tumors

78 (9.8%)

2 (2.6%)

1 (1.3%)

 Partial parotidectomy

441 (55.5%)

29 (6.6%)

12 (2.7%)

 Superficial parotidectomy

187 (23.6%)

13 (7.0%)

10 (5.3%)

 Total parotidectomy

88 (11.1%)

29 (33.0%)

18 (20.5%)

Types of surgery

 Primary parotidectomy

753 (94.8%)

62 (8.2%)

33 (4.4%)

 Revision parotidectomy (Recurrent tumors)

41 (5.2%)

11 (26.8%)

8 (19.5%)

  1. aTemporary facial weakness: Status of facial expression at postoperative day 1 to 5
  2. bPermanent facial weakness: Status of facial expression at more than 6 months postoperatively
  3. cMalignant tumors: facial nerve sacrifices in 21 cases with malignant tumors, even with intact facial nerve function pre-operatively